← All trials
NCT05804656
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 13, 2023
- Primary completion
- Aug 29, 2023
- Completion date
- Nov 20, 2023
- First posted
- Apr 7, 2023
- Last posted
- Dec 12, 2023
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CKD Bio CorporationLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.